Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/jcm11040968
Keywords
non-alcoholic fatty liver disease; NAFLD; non-alcoholic steatohepatitis; NASH; type 2 diabetes; cardiovascular disease; cardiovascular complications; CVD
Categories
Ask authors/readers for more resources
Non-alcoholic fatty liver disease (NAFLD) is a common hepatic manifestation of metabolic syndrome and is strongly associated with cardiovascular disease. It is also independently associated with microvascular conditions such as chronic kidney disease and neuropathy.
Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome. To date, NAFLD is the most frequent chronic liver disease seen day by day in clinical practice across most high-income countries, affecting nearly 25-30% of adults in the general population and up to 70% of patients with T2DM. Over the last few decades, it clearly emerged that NAFLD is a multisystemic disease and that the leading cause of death among patients with NAFLD is cardiovascular disease (CVD). Indeed, several observational studies and some meta-analyses have documented that NAFLD, especially its advanced forms, is strongly associated with fatal and non-fatal cardiovascular events, as well as with specific cardiac complications, including sub-clinical myocardial alteration and dysfunction, heart valve diseases and cardiac arrhythmias. Importantly, across various studies, these associations remained significant after adjustment for established cardiovascular risk factors and other confounders. Additionally, several observational studies and some meta-analyses have also reported that NAFLD is independently associated with specific microvascular conditions, such as chronic kidney disease and distal or autonomic neuropathy. Conversely, data regarding a potential association between NAFLD and retinopathy are scarce and often conflicting. This narrative review will describe the current evidence about the association between NAFLD and the risk of macro- and microvascular manifestations of CVD, especially in patients with T2DM. We will also briefly discuss the biological mechanisms underpinning the association between NAFLD and its advanced forms and macro- and microvascular CVD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available